Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease

INTRODUCTION: In the cardiovascular outcome trials (CVOT) EMPA-REG OUTCOME, TECOS and SAVOR-TIMI 53, empagliflozin [sodium/glucose cotransporter 2 (SGLT2) inhibitor], sitagliptin and saxagliptin [both dipeptidyl peptidase 4 (DPP4) inhibitors] + standard of care (SoC) were compared to SoC in patients...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Diabetes Ther
Main Authors: Ramos, Mafalda, Foos, Volker, Ustyugova, Anastasia, Hau, Nikco, Gandhi, Pranav, Lamotte, Mark
Format: Artigo
Sprog:Inglês
Udgivet: Springer Healthcare 2019
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6848565/
https://ncbi.nlm.nih.gov/pubmed/31602601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-00701-3
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker